• Ascletis launched an open-market share buyback plan, authorizing up to HK$300 million in repurchases, funded from internal resources.
• The mandate allows repurchases of up to 106,137,084 shares, equal to 10% of issued shares excluding treasury shares as of June 29, 2026.
• Buybacks will run from time to time, subject to market conditions, with no shares repurchased yet under the mandate.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260630-12221828), on June 30, 2026, and is solely responsible for the information contained therein.